Propel Bio Management
ARTV icon

Propel Bio Management’s Artiva Biotherapeutics ARTV Stock Holding History

Propel Bio Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.96M Hold
696,436
– – 2.63% 13
2026
Q2 		$6.76M Buy
696,436
+550,067
+376% +$5.01M 3.54% 9
2026
Q1 		$950K Buy
+146,369
New +$724K 0.6% 36

Other funds holding ARTV

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Propel Bio Management's ARTV Position: Q3 2026 in Review

Propel Bio Management held its Artiva Biotherapeutics (ARTV) position steady in Q3 2026 at 696,436 shares worth $4.96M. The position accounts for 2.63% of the portfolio, ranked #13.

Propel Bio Management first reported a position in ARTV in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.76M in Q2 2026. 57 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Propel Bio Management held 696,436 shares of Artiva Biotherapeutics worth $4.96M as of Q3 2026.
  • Propel Bio Management left its Artiva Biotherapeutics share count unchanged in Q3 2026.
  • Artiva Biotherapeutics made up 2.63% of Propel Bio Management's portfolio in Q3 2026, its #13 holding.
  • Propel Bio Management first reported a position in Artiva Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Propel Bio Management's Artiva Biotherapeutics position peaked at $6.76M in Q2 2026.
  • 57 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Propel Bio Management's 13F filing for Q3 2026, filed 13 Nov 2026.